{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:33:50Z","timestamp":1794893630953,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172632"],"award-info":[{"award-number":["82172632"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Angiogenesis is a hallmark of hepatocellular carcinoma (HCC), yet most cases resist antiangiogenic drugs (AADs) targeting VEGFA-VEGFR2, and the molecular mechanisms remain largely unknown. Here, we show that apolipoprotein A2 (APOA2) mediates endothelial-to-mesenchymal transition and reprograms cancer lipid metabolism, inducing AAD resistance in HCC. This occurs via downregulating VEGFR2 in vascular endothelial cells and promoting high cancer cell proliferation with low apoptosis. The whole transcriptome sequencing of unresectable human HCC specimens revealed elevated expression of APOA2 in the AAD-resistant group. Furthermore, the overexpression of APOA2 confirmed resistance to AAD therapy in an HCC-bearing mouse model. AAD treatment had no effect on tumor angiogenesis in HCC overexpressing APOA2, while cancer cells exhibited increased proliferation and reduced apoptosis. Mechanistically, proteomic analysis verified that APOA2 significantly upregulates transforming growth factor-beta (TGF-\u03b2) related proteins. Furthermore, the secretion of TGF-\u03b2 was markedly increased in HCC cell culture medium and the blood of HCC-bearing mice after APOA2 overexpression. On the one hand, TGF-\u03b2 reduced VEGFR-2 expression and increased mesenchymal gene expression in ECs. On the other hand, TGF-\u03b2 initiated fatty acid (FA) oxidation metabolic reprogramming and increased uptake of free FAs, stimulating cancer cell proliferation. Furthermore, inhibition of TGF-\u03b2 eliminated APOA2-mediated EndoMT and cancer lipid metabolism reprogramming. Notably, HCC with high expression of APOA2 relied on TGF-\u03b2 to promote cell proliferation and angiogenesis, and pharmacological loss of TGF-\u03b2 function can reduce angiogenesis and malignant tumor proliferation. These findings reveal an effective cancer therapy concept by inhibition of TGF-\u03b2, targeting angiogenesis and lipid metabolism reprogramming.<\/jats:p>","DOI":"10.1038\/s41420-026-02984-5","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:35:50Z","timestamp":1772213750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["APOA2-mediated endothelial mesenchymal transition and cancer lipid metabolism reprogramming confers antiangiogenic drug resistance through TGF-\u03b2"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3081-9126","authenticated-orcid":false,"given":"Su","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manqing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3345-8005","authenticated-orcid":false,"given":"Hua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8759-4395","authenticated-orcid":false,"given":"Ti","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"2984_CR1","doi-asserted-by":"crossref","unstructured":"Luo JX, Zhang Y, Hu XY, Xiang N. Interferon therapy improves survival in patients with hepatitis B virus-related hepatocellular carcinoma after curative surgery: a meta-analysis. Hepatol Int. 2024;18:63\u201372","DOI":"10.1007\/s12072-023-10618-6"},{"key":"2984_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","volume":"158","author":"ZJ Brown","year":"2023","unstructured":"Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM, et al. Management of hepatocellular carcinoma: a review. JAMA Surg. 2023;158:410\u201320.","journal-title":"JAMA Surg"},{"key":"2984_CR3","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402:1133\u201346.","journal-title":"Lancet"},{"key":"2984_CR4","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3748\/wjg.v29.i10.1551","volume":"29","author":"W Leowattana","year":"2023","unstructured":"Leowattana W, Leowattana T, Leowattana P. Systemic treatment for unresectable hepatocellular carcinoma. World J Gastroenterol. 2023;29:1551\u201368.","journal-title":"World J Gastroenterol"},{"key":"2984_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","volume":"79","author":"L Rimassa","year":"2023","unstructured":"Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023;79:506\u201315.","journal-title":"J Hepatol"},{"key":"2984_CR6","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41580-023-00631-w","volume":"24","author":"L P\u00e9rez-Guti\u00e9rrez","year":"2023","unstructured":"P\u00e9rez-Guti\u00e9rrez L, Ferrara N. Biology and therapeutic targeting of vascular endothelial growth factor A. Nat Rev Mol Cell Biol. 2023;24:816\u201334.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2984_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05982-z","volume":"9","author":"T Liu","year":"2018","unstructured":"Liu T, Ma W, Xu H, Huang M, Zhang D, He Z, et al. PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma. Nat Commun. 2018;9:3439.","journal-title":"Nat Commun"},{"key":"2984_CR8","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/s42255-023-00883-y","volume":"5","author":"C Wang","year":"2023","unstructured":"Wang C, Huang M, Lin Y, Zhang Y, Pan J, Jiang C, et al. ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 and confers resistance to antiangiogenic therapy. Nat Metab. 2023;5:1765\u201386.","journal-title":"Nat Metab"},{"key":"2984_CR9","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1016\/j.cell.2023.09.011","volume":"186","author":"D Mossmann","year":"2023","unstructured":"Mossmann D, M\u00fcller C, Park S, Ryback B, Colombi M, Ritter N, et al. Arginine reprograms metabolism in liver cancer via RBM39. Cell. 2023;186:5068\u201383.e23.","journal-title":"Cell"},{"key":"2984_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-023-01498-2","volume":"16","author":"Jin HR","year":"2023","unstructured":"HR Jin, Wang J, Wang ZJ, Xi MJ, Xia BH, Deng K, et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J Hematol Oncol. 2023;16:103.","journal-title":"J Hematol Oncol"},{"key":"2984_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cmet.2018.05.005","volume":"28","author":"H Iwamoto","year":"2018","unstructured":"Iwamoto H, Abe M, Yang Y, Cui D, Seki T, Nakamura M, et al. Cancer lipid metabolism confers antiangiogenic drug resistance. Cell Metab. 2018;28:104\u201317.e5.","journal-title":"Cell Metab"},{"key":"2984_CR12","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1021\/acs.jproteome.2c00804","volume":"22","author":"C Lloyd-Jones","year":"2023","unstructured":"Lloyd-Jones C, Dos Santos Seckler H, DiStefano N, Sniderman A, Compton PD, Kelleher NL, et al. Preparative electrophoresis for hdl particle size separation and intact-mass apolipoprotein proteoform analysis. J Proteome Res. 2023;22:1455\u201365.","journal-title":"J Proteome Res"},{"key":"2984_CR13","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1111\/jgh.16302","volume":"38","author":"S Futagami","year":"2023","unstructured":"Futagami S, Agawa S, Nakamura K, Watanabe Y, Habiro M, Kawawa R, et al. Apolipoprotein A2 isoforms associated with exocrine pancreatic insufficiency in early chronic pancreatitis. J Gastroenterol Hepatol. 2023;38:1949\u201357.","journal-title":"J Gastroenterol Hepatol"},{"key":"2984_CR14","first-page":"503","volume":"33","author":"K Honda","year":"2022","unstructured":"Honda K. Risk stratification of pancreatic cancer by a blood test for apolipoprotein A2-isoforms. Cancer Biomark Sect A Dis Markers. 2022;33:503\u201312.","journal-title":"Cancer Biomark Sect A Dis Markers"},{"key":"2984_CR15","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1002\/ijc.31900","volume":"144","author":"K Honda","year":"2019","unstructured":"Honda K, Katzke VA, Husing A, Okaya S, Shoji H, Onidani K, et al. CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation. Int J Cancer. 2019;144:1877\u201387.","journal-title":"Int J Cancer"},{"key":"2984_CR16","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41568-023-00591-5","volume":"23","author":"Q Zeng","year":"2023","unstructured":"Zeng Q, Mousa M, Nadukkandy AS, Franssens L, Alnaqbi H, Alshamsi FY, et al. Understanding tumour endothelial cell heterogeneity and function from single-cell omics. Nat Rev Cancer. 2023;23:544\u201364.","journal-title":"Nat Rev Cancer"},{"key":"2984_CR17","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.cmet.2023.06.006","volume":"35","author":"CA Recatal\u00e1","year":"2023","unstructured":"Recatal\u00e1 CA, Santoro MM. The glucose-to-acetate metabolic flux that drives endothelial-to-mesenchymal transition via TGF-\u03b2 signaling. Cell Metab. 2023;35:1093\u20135.","journal-title":"Cell Metab"},{"key":"2984_CR18","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3389\/fcell.2020.00747","volume":"8","author":"N Clere","year":"2020","unstructured":"Clere N, Renault S, Corre I. Endothelial-to-mesenchymal transition in cancer. Front Cell Dev Biol. 2020;8:747.","journal-title":"Front Cell Dev Biol"},{"key":"2984_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01569-x","volume":"21","author":"D Peng","year":"2022","unstructured":"Peng D, Fu M, Wang M, Wei Y, Wei X. Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022;21:104.","journal-title":"Mol Cancer"},{"key":"2984_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13045-022-01349-6","volume":"15","author":"X Shi","year":"2022","unstructured":"Shi X, Yang J, Deng S, Xu H, Wu D, Zeng Q, et al. TGF-\u03b2 signaling in the tumor metabolic microenvironment and targeted therapies. J Hematol Oncol. 2022;15:135.","journal-title":"J Hematol Oncol"},{"key":"2984_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.canlet.2020.12.031","volume":"501","author":"S Zhang","year":"2021","unstructured":"Zhang S, Cao M, Hou Z, Gu X, Chen Y, Chen L, et al. Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma. Cancer Lett. 2021;501:147\u201361.","journal-title":"Cancer Lett"},{"key":"2984_CR22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.celrep.2016.12.034","volume":"18","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, O\u2019Leary MN, Peri S, Wang M, Zha J, Melov S, et al. Ribosomal proteins Rpl22 and Rpl22l1 control morphogenesis by regulating pre-mRNA splicing. Cell Rep. 2017;18:545\u201356.","journal-title":"Cell Rep"},{"key":"2984_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202207020","volume":"10","author":"H Sun","year":"2023","unstructured":"Sun H, Liu F, Lin Z, Jiang Z, Wen X, Xu J, et al. Silencing of NOTCH3 signaling in meniscus smooth muscle cells inhibits fibrosis and exacerbates degeneration in a HEYL-dependent manner. Adv Sci. 2023;10:e2207020.","journal-title":"Adv Sci"},{"key":"2984_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21828-7","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang X, Wang J, Tsui YM, Shi C, Wang Y, Zhang X, et al. RALYL increases hepatocellular carcinoma stemness by sustaining the mRNA stability of TGF-\u03b22. Nat Commun. 2021;12:1518.","journal-title":"Nat Commun"},{"key":"2984_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13020-021-00474-7","volume":"16","author":"Y Peng","year":"2021","unstructured":"Peng Y, Zhang Y, Zhang Y, Wang X, Xia Y. Pterostilbene alleviates pulmonary fibrosis by regulating ASIC2. Chin Med. 2021;16:66.","journal-title":"Chin Med"},{"key":"2984_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.18632\/genesandcancer.199","volume":"11","author":"K Ohshiro","year":"2020","unstructured":"Ohshiro K, Chen J, Srivastav J, Mishra L, Mishra B. Alterations in TGF-\u03b2 signaling leads to high HMGA2 levels potentially through modulation of PJA1\/SMAD3 in HCC cells. Genes cancer. 2020;11:43\u201352.","journal-title":"Genes cancer"},{"key":"2984_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ajcn\/nqy136","volume":"108","author":"HJ Pownall","year":"2018","unstructured":"Pownall HJ. Rethinking apolipoprotein A-II in lipid metabolism. Am J Clin Nutr. 2018;108:4\u20135.","journal-title":"Am J Clin Nutr"},{"key":"2984_CR28","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.7150\/ijbs.69802","volume":"18","author":"J Quan","year":"2022","unstructured":"Quan J, Cheng C, Tan Y, Jiang N, Liao C, Liao W, et al. Acyl-CoA synthetase long-chain 3-mediated fatty acid oxidation is required for TGF\u03b21-induced epithelial-mesenchymal transition and metastasis of colorectal carcinoma. Int J Biol Sci. 2022;18:2484\u201396.","journal-title":"Int J Biol Sci"},{"key":"2984_CR29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.semcancer.2023.04.007","volume":"92","author":"T Watabe","year":"2023","unstructured":"Watabe T, Takahashi K, Pietras K, Yoshimatsu Y. Roles of TGF-\u03b2 signals in tumor microenvironment via regulation of the formation and plasticity of vascular system. Semin Cancer Biol. 2023;92:130\u20138.","journal-title":"Semin Cancer Biol"},{"key":"2984_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12860-017-0127-y","volume":"18","author":"M Jarad","year":"2017","unstructured":"Jarad M, Kuczynski EA, Morrison J, Viloria-Petit AM, Coomber BL. Release of endothelial cell associated VEGFR2 during TGF-\u03b2 modulated angiogenesis in vitro. BMC Cell Biol. 2017;18:10.","journal-title":"BMC Cell Biol"},{"key":"2984_CR31","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, et al. TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538\u201343.","journal-title":"Nature"},{"key":"2984_CR32","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544\u20138.","journal-title":"Nature"},{"key":"2984_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jhep.2023.10.006","volume":"80","author":"L Zhang","year":"2024","unstructured":"Zhang L, Xu J, Zhou S, Yao F, Zhang R, You W, et al. Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma. J Hepatol. 2024;80:82\u201398.","journal-title":"J Hepatol"},{"key":"2984_CR34","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","volume":"5","author":"W Tang","year":"2020","unstructured":"Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5:87.","journal-title":"Signal Transduct Target Ther"},{"key":"2984_CR35","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2174\/1568009622666220428111327","volume":"22","author":"J Guo","year":"2022","unstructured":"Guo J, Zhao J, Xu Q, Huang D. Resistance of lenvatinib in hepatocellular carcinoma. Curr Cancer Drug Targets. 2022;22:865\u201378.","journal-title":"Curr Cancer Drug Targets"},{"key":"2984_CR36","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28:1599\u2013611.","journal-title":"Nat Med"},{"key":"2984_CR37","doi-asserted-by":"publisher","first-page":"14906","DOI":"10.1073\/pnas.1415825111","volume":"111","author":"J Honek","year":"2014","unstructured":"Honek J, Seki T, Iwamoto H, Fischer C, Li J, Lim S, et al. Modulation of age-related insulin sensitivity by VEGF-dependent vascular plasticity in adipose tissues. Proc Natl Acad Sci USA. 2014;111:14906\u201311.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2984_CR38","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nature12207","volume":"498","author":"L Maddaluno","year":"2013","unstructured":"Maddaluno L, Rudini N, Cuttano R, Bravi L, Giampietro C, Corada M, et al. EndoMT contributes to the onset and progression of cerebral cavernous malformations. Nature. 2013;498:492\u20136.","journal-title":"Nature"},{"key":"2984_CR39","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1172\/JCI84876","volume":"126","author":"M Huang","year":"2016","unstructured":"Huang M, Liu T, Ma P, Mitteer RA Jr, Zhang Z, Kim HJ, et al. c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma. J Clin Investig. 2016;126:1801\u201314.","journal-title":"J Clin Investig"},{"key":"2984_CR40","doi-asserted-by":"publisher","first-page":"16653","DOI":"10.1074\/jbc.M115.636944","volume":"290","author":"X Xu","year":"2015","unstructured":"Xu X, Tan X, Tampe B, Sanchez E, Zeisberg M, Zeisberg EM. Snail is a direct target of hypoxia-inducible factor 1\u03b1 (HIF1\u03b1) in hypoxia-induced endothelial to mesenchymal transition of human coronary endothelial cells. J Biol Chem. 2015;290:16653\u201364.","journal-title":"J Biol Chem"},{"key":"2984_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1083\/jcb.200409067","volume":"168","author":"RE Bachelder","year":"2005","unstructured":"Bachelder RE, Yoon SO, Franci C, de Herreros AG, Mercurio AM. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol. 2005;168:29\u201333.","journal-title":"J Cell Biol"},{"key":"2984_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.896752","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, Hu H, Yuan X, Fan X, Zhang C. Advances in immune checkpoint inhibitors for advanced hepatocellular carcinoma. Front Immunol. 2022;13:896752.","journal-title":"Front Immunol"},{"key":"2984_CR43","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","volume":"72","author":"AL Cheng","year":"2020","unstructured":"Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72:307\u201319.","journal-title":"J Hepatol"},{"key":"2984_CR44","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.stem.2024.06.009","volume":"31","author":"JL Thangaraj","year":"2024","unstructured":"Thangaraj JL, Coffey M, Lopez E, Kaufman DS. Disruption of TGF-beta signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells. Cell Stem Cell. 2024;31:1327\u201343 e5.","journal-title":"Cell Stem Cell"},{"key":"2984_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64860-7","volume":"16","author":"MML Lei","year":"2025","unstructured":"Lei MML, Leung CON, Leung RWH, Wu XQ, Chung KPS, Gu CYJ, et al. Wild-type KRAS activation drives evasion of interferon-mediated immunity and resistance to immunotherapy in hepatocellular carcinoma. Nat Commun. 2025;16:9913.","journal-title":"Nat Commun"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-02984-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-02984-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-02984-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:01:57Z","timestamp":1774026117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-02984-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2984"],"URL":"https:\/\/doi.org\/10.1038\/s41420-026-02984-5","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declared no competing interests","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experimental protocols involving human participants and human tissue samples were approved by the Tianjin Medical University Cancer Institute Ethics Committee. All methods were performed in accordance with the relevant guidelines and regulations, including the Declaration of Helsinki and its subsequent amendments or comparable ethical standards.Human tumor tissues used in this study were obtained from Tianjin Medical University Cancer Institute and Hospital. Informed consent was obtained from all participants prior to sample collection. Written informed consent was provided by each patient for the use of their tissue samples in research. The tissue providers confirmed that all samples were collected in compliance with applicable laws and institutional ethical requirements.All animal experiments were carried out in accordance with a protocol approved by the ethics committee of the Institutional Animal Care of Tianjin Medical University Cancer Institute and Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}}],"article-number":"119"}}